Fusidic acid for Behçet's colitis: a novel approach to T-cell specific immunosuppressive therapy

TY - JOUR

T1 - Fusidic acid for Behçet's colitis

T2 - a novel approach to T-cell specific immunosuppressive therapy

AU - Langholz, E

AU - Brynskov, J

AU - Freund, L G

AU - Bendtzen, K

PY - 1991/6

Y1 - 1991/6

N2 - A 33-year-old patient suffered from recurring Beh,cet's colitis despite treatment with corticosteroids and later cyclosporin. The patient was then successfully shifted from cyclosporin, a T-cell specific immunosuppressant, to fusidic acid treatment (500 mg t.i.d.). During fusidic acid treatment, he went into complete remission, and his prednisolone dose could be reduced from 30 to 5 mg/day. The case report substantiates recent in vitro data indicating that fusidic acid has a similar effect on T-cell function as cyclosporin. It is suggested that the effect of fusidic acid in other chronic immunoinflammatory diseases should be examined.

AB - A 33-year-old patient suffered from recurring Beh,cet's colitis despite treatment with corticosteroids and later cyclosporin. The patient was then successfully shifted from cyclosporin, a T-cell specific immunosuppressant, to fusidic acid treatment (500 mg t.i.d.). During fusidic acid treatment, he went into complete remission, and his prednisolone dose could be reduced from 30 to 5 mg/day. The case report substantiates recent in vitro data indicating that fusidic acid has a similar effect on T-cell function as cyclosporin. It is suggested that the effect of fusidic acid in other chronic immunoinflammatory diseases should be examined.

KW - Adult

KW - Behcet Syndrome/complications

KW - Colitis/complications

KW - Fusidic Acid/therapeutic use

KW - Humans

KW - Immunosuppressive Agents/therapeutic use

KW - Male

KW - T-Lymphocytes/drug effects

M3 - Journal article

C2 - 1868757

SN - 0907-8916

VL - 38

SP - 284

JO - Danish Medical Bulletin

JF - Danish Medical Bulletin

IS - 3

ER -